Detalle Publicación

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Autores: Usmani, S. Z. (Autor de correspondencia); Schjesvold, F.; Oriol, A. ; Karlin, L.; Cavo, M. ; Rifkin, R. M. ; Yimer, H. A.; LeBlanc, R. ; Takezako, N.; McCroskey, R. D.; Lim, A. B. M. ; Suzuki, K. ; Kosugi, H.; Grigoriadis, G.; Avivi, I.; Facon, T. ; Jagannath, S.; Lonial, S. ; Ghori, R. U. ; Farooqui, M. Z. H. ; Marinello, P.; San Miguel Izquierdo, Jesús; KEYNOTE-185 Investigators
Título de la revista: THE LANCET. HAEMATOLOGY
ISSN: 2352-3026
Volumen: 6
Número: 9
Páginas: e448 -e458
Fecha de publicación: 2019
Lugar: WOS
Background: Lenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combination is likely to improve treatment efficacy. KEYNOTE-185 assessed the efficacy and safety of lenalidomide and dexamethasone with and without pembrolizumab in patients with previously untreated multiple myeloma. Here, we present the results of an unplanned interim analysis done to assess the benefit-risk of the combination at the request of the US Food and Drug Administration (FDA). Methods: KEYNOTE-185 was a randomised, open-label, phase 3 trial done at 95 medical centres across 15 countries (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, New Zealand, Norway, Russia, South Africa, Spain, UK, and USA). Transplantation-ineligible patients aged 18 years and older with newly diagnosed multiple myeloma, Eastern Cooperative Oncology Group performance status of 0 or 1, and who were treatment naive were enrolled, and randomly assigned 1:1 to receive either pembrolizumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone alone using an interactive voice or integrated web response system. Patients received oral lenalidomide 25 mg on days 1-21 and oral dexamethasone 40 mg on days 1, 8, 15, and 22 of repeated 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The primary endpoint was progression-free survival, which was investigator-ass